As per the terms of the agreement, Minophagen is expected to get license for the development and commercialization of Eisai‘s Bexarotene in Japan.
However, Eisai is expected to hold the option to co-promote the product in Japan, if and when it is approved.
Eisai has acquired Bexarotene from Ligand Pharmaceuticals in October 2006.